Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 February 2022 | Story Leonie Bolleurs | Photo Supplied
Unique PhD Journeys
Prof Liezel Lues and her two doctoral students on graduation day. On the left is Dr Modeni Sibande, who is looking forward to ensuring that Public Administration and Management remains relevant to contemporary evolving issues in society. On the right is Dr Maréve Biljohn, who as a student has always shown commitment to do her best in every aspect of her PhD journey.

In nature, one often comes across cool and surreal phenomena. Experiencing rare happenings in the academia is an altogether different encounter. One that Prof Liezel Lues, Professor in the Department of Public Administration and Management at the University of the Free State (UFS), explains as winning the lottery.

Two of Prof Lues’ doctoral students – representing two different institutions – graduated in 2018. Four years later, on the exact same date, 1 March 2022, Drs Maréve Biljohn and Modeni Sibanda will take up their new positions, respectively as Head of the Department of Public Administration and Management at the UFS and Head of the Department of Public Administration at the University of Fort Hare.

 

Social innovation and service delivery

Dr Biljohn, currently Senior Lecturer in the department, did her thesis on the topic: Social innovation and service delivery by local government: a comparative perspective. With work experience in local government, Dr Biljohn had a good idea of the problems that underpin poor service delivery in this sphere of government.

Public participation in integrated development planning: a case study of Buffalo City Metropolitan Municipality, was the title of Dr Sibanda’s thesis. The study revealed how individuals and communities navigate forms of power and raise the critical consciousness of municipal residents, communities, and public officials.

According to Dr Sibanda, his study was motivated by the need to explore how public participation power dynamics influence Integrated Development Planning outcomes.

He believes by doing so, the complexity of how individuals and communities navigate forms of power in public participation platforms and spaces would be unravelled. Unravelling such public participation power dynamics, he says, would raise critical consciousness and address and challenge visible, hidden, and invisible forms of power on these public platforms and spaces. “Often public participation platforms and spaces neglect and ignore the capacity of such spaces to manage the pervasive, complex power dynamics among stakeholders in municipal strategic development planning processes. This focus to my PhD therefore sought to fill that knowledge gap,” adds Dr Sibanda.

Prof Lues says the value link to their research is buoyed in the South African Local Government. “They have both established a niche area that addresses the challenges South African municipalities face,” she adds.


“There is no doubt that they are suitable for the position of head of department at this point.”


Achieving a coveted status in their careers

On experiencing this unique journey, Prof Lues says: “Of all the relations, a relation between a promoter and a student is the most inspiring and admirable one. Any promoter takes the utmost pride when his/her taught students achieve coveted status in their respective careers. To me, it feels like winning the lottery – twice.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept